GlaxoSmithKline Plans Vaccine Plant in Singapore
GlaxoSmithKline PLC (GSK, London, UK) will invest more than GBP102 million ($188 million) over the next four years in a vaccine manufacturing plant in Singapore.
GlaxoSmithKline PLC (GSK, London, UK, www.gsk.com) will invest more than GBP102 million($188 million) over the next four years in a vaccine manufacturingplant in Singapore.
The facility will be dedicated to the primary production of pediatricvaccines. Once operational, the facility will manufacture GSK'sconjugate vaccine, which provides protection against Streptococcus pneumoniae andnontypeable Haemophilus influenzae.
In 2005, GSK opened its Center for Research in Cognitive andNeurodegenerative Disorders in Singapore's Biopolis and also announcedplans to build a research and development pilot plant at its globalmanufacturing supply site in Jurong.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
